'Oscars of Science' Honour Gene Therapy Pioneers Who Cured Inherited Blindness and Sickle Cell Disease

<p>The <strong>2026 Breakthrough Prizes</strong> — often called the <em>&ldquo;Oscars of Science&rdquo;</em> — have been awarded, and this year's winners include researchers whose work is nothing short of miraculous: <strong>curing inherited blindness, sickle cell disease, and beta-thalassemia</strong> through gene therapy.</p><h2>The Winners</h2><p>Six prizes of <strong>$3 million each</strong> were awarded on April 18, 2026, in Los Angeles. The Life Sciences prizes went to:</p><ul><li><strong>Jean Bennett, Katherine A. High, and Albert Maguire</strong> — for developing <strong>Luxturna</strong>, the first FDA-approved gene therapy for inherited retinal disease. Children who were going blind can now see.</li><li><strong>Stuart H. Orkin and Swee Lay Thein</strong> — for discoveries that led to <strong>CRISPR-based gene editing therapies</strong> for sickle cell disease and beta-thalassemia. Their work identified the BCL11A gene as a key target, enabling treatments that are effectively curing these devastating blood disorders.</li><li><strong>Rosa Rademakers and Bryan Traynor</strong> — for identifying a major genetic cause of <strong>ALS (motor neurone disease) and frontotemporal dementia</strong>, opening doors to future treatments.</li></ul><h2>From 'It Will Never Work' to Nobel-Level Impact</h2><p>Many of these researchers spent decades pursuing gene therapy when the scientific establishment dismissed it as impossible. <em>&ldquo;I can't tell you how many times people said it will never work,&rdquo;</em> one laureate told reporters.</p><p>Their persistence has paid off spectacularly. Luxturna has restored sight to children with inherited blindness. The CRISPR-based therapy Casgevy — built on Orkin and Thein's foundational work — is now <strong>approved in multiple countries</strong> and producing what doctors describe as functional cures for sickle cell disease.</p><h2>Why This Matters</h2><p>Sickle cell disease affects an estimated <strong>20 million people worldwide</strong>, predominantly in Africa and among people of African descent. Beta-thalassemia affects millions more across the Mediterranean, Middle East, and Asia. These are not niche conditions — they are among the most common genetic diseases on Earth.</p><p>The fact that we now have <strong>functional cures</strong> for some of these conditions — and are rapidly developing more — represents one of the greatest medical achievements of our era.</p><p>This year's total prize money reached <strong>$18.75 million</strong>, bringing the Breakthrough Prize's lifetime total to over <strong>$340 million</strong> invested in celebrating scientific excellence.</p><p><em>Sources: Breakthrough Prize Foundation, The Scientist, IFLScience, Global Genes (April 18, 2026)</em></p>